To the Editor—We read with interest the article by Ramsay and Luterman1 and accompanying editorial2 discussing the use of high-dose dexmedetomidine as a single-agent intravenous anesthetic. We have several concerns, both with the technique described and the journal’s editorial position.

As to the case series itself, we wonder what was the basis for the clinical choice to use doses of dexmedetomidine at more than 7 to 50 times the recommended dose range of 0.2–0.7 μg·kg⁻¹·h⁻¹ as the sole anesthetic. Ebert et al.’s work with volunteers3 was extremely limited and in no way established dexmedetomidine as a safe single-agent anesthetic. Indeed, doses of dexmedetomidine lower than those in the case series have been recently reported as “accidental overdose” and are accompanied by guidelines for the management of same.4 Although Ramsay and Luterman’s cases imply that the doses were increased when the patients could not tolerate the procedures at lower dose levels, there is no mention of the initial anesthetic plan. Did the authors undertake the anesthetics with the expectation of using dexmedetomidine at massive, unstudied doses? Given the properties of dexmedetomidine at its usual clinical dose range, it is unlikely that patients would be able to tolerate the procedures described without either supplementation or rapid escalation to massive doses, as actually occurred. We find no convincing evidence in the literature to believe that their course of action could be chosen with confidence in its safety and efficacy. The intraoperative management of the cases is also unusual. We fail to understand their need to avoid the use of supplemental oxygen except when absolutely necessary. The argument regarding electrocautery is unconvinving. It is almost as if the decreased margin of safety is used as a demonstration of dexmedetomidine’s properties with respect to maintenance of ventilation. In the two cases that did not receive supplemental oxygen, were the patients subsequently placed on oxygen in the postanesthesia care unit? Finally, we question the assertion that recovery time in these patients was not significantly prolonged when compared with many conventional anesthetic techniques. A recovery time and postanesthesia care unit stay of 2 to 3 h is considered by many to be significantly prolonged and is not a desirable side effect.

We are therefore concerned that Anesthesiology tacitly endorses this anesthetic technique by calling it “another arrow for the clinician’s quiver” in the accompanying editorial. On the basis of Ebert et al.’s two volunteered and the three cases described by Ramsay and Luterman, are we to assume that this is now an acceptable practice? Certainly, we all daily administer many medications “off-label” in a safe and reasonable manner. There comes a point, however, when the off-label use of a drug crosses the line of “reasonable” and becomes a deviation from the standard of care. Until properly controlled, Institutional Review Board reviewed clinical studies (with appropriate informed patient consent) are conducted addressing safety and efficacy issues of the doses in question, it is premature to call single-agent intravenous dexmedetomidine “another arrow for the clinician’s quiver.” A case report or small series of cases should highlight an unusual occurrence, pathology, or unanticipated anesthetic intervention, rather than act as a proving ground for new anesthetic techniques. There is nothing in the article to suggest that the patients involved provided informed consent as to the unusual nature of the anesthetic. Similarly, it does not appear that an Institutional Review Board or hospital ethics committee was consulted regarding this “case series.” The practice of anesthesiology is neither a contest of skills nor a game of what one can get away with. The essence of the practice of anesthesiology is the planning and administration of the safest and most efficient anesthetic for a given individual patient using principles grounded in science and controlled clinical studies. An unusual technique that worked in three patients does not rise to this standard and sidesteps the checks and balances of ethical scientific investigation.

Finally, the lack of complete disclosure of conflicts of interest on Dr. Ebert’s part is disturbing. The annotation states, “Dr. Ebert is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this editorial.” This may be true only in the strictest and most limited interpretation of the statement, but ignores Dr. Ebert’s long and close association with Abbott Laboratories (Abbott Park, IL) and previous substantial financial support and honoraria. In fact, the study cited by Ebert in the editorial, examining high-dose dexmedetomidine in volunteers,9 was itself supported by a grant from Abbott Laboratories. At best, this is disingenuous. The casual reader of the journal should be fully aware that an unproven anesthetic technique, utilizing an expensive drug manufactured by Hospira, Inc. (Lake Forest, IL), a wholly-owned spin-off company of Abbott Laboratories, is advocated by an Abbott-funded investigator and is trumpeted by editorial writers with a long history of close association and support from Abbott Laboratories. It is difficult to understand how one can consider this an objective review of scientific data.

George Mychaskiw, II, D.O.,* Ahmed E. Badr, M.D. * University of Mississippi School of Medicine, Jackson, Mississippi. gmychaskiw@anesthesia.umsmed.edu

References

1. Ramsay MAE, Luterman DL: Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004;101:787–90
2. Ebert T, Maze M: Dexmedetomidine: Another arrow for the clinician’s quiver. Anesthesiology 2004;101:568–70

In Reply—I believe Dr. Mychaskiw and Dr. Badr indicate four areas of concern in their Letter to the Editor. The first relates to the clinical choice of using extremely high doses of dexmedetomidine, the second refers to case management and oxygen therapy, the third is the perception that the journal endorses the technique of “off-label” use of dexmedetomidine, and the fourth has to do with my conflict of interest disclosure. I believe the first two concerns are questions about the editorial review process. Clearly, expert reviewers provided sufficient enthusiasm to have the case reports published. I was not involved in the review and cannot comment except on one area of concern; my personal belief is oxygen is generally good for patients, even during spontaneous ventilation.

I do wish to comment on the third issue of the Journal’s perceived “endorsement” of the “off-label” use of dexmedetomidine in the clinical care of several difficult cases. Case reports are meant to draw attention to important and novel clinical situations, treatments, and
complications. I commend the Journal for asking for expert commentary on the described use of dexmedetomidine with a focus on further education and safety. With the editorial by Dr. Maze and myself, the clinician might not have been aware of the "caveats" and "potential side effects of large concentrations of dexmedetomidine" described in detail in our editorial. The concerns we expressed were: 1) reports of apnea from bolus administration of dexmedetomidine in patients with a history of sleep apnea; 2) hypertension, both pulmonary and systemic; and 3) bradycardia. Clearly an endorsement of "off-label" use of dexmedetomidine was not intended or given. However, the off-label use of anesthesia-related drugs is extensive. Consider a careful read of the Food and Drug Administration labeling of drugs such as the use of the antiepileptic drug gabapentin for pain syndromes, dexamethasone for postoperative nausea and vomiting, intrathecal use of fentanyl, meperidine for shivering, and many drugs used in the pediatric population. The list of accepted drug usages that are not supported by Food and Drug Administration labeling is lengthy. With each unapproved use came case reports followed by controversy (e.g., letters to editors), followed by controlled studies and ultimately accepted practice when the risk/benefit ratio was proven despite package labeling. Finally, Drs. Mychaskiw and Badr express concern with my attestation that I maintain no financial interest or commercial activity in the topic of our editorial and further perceive that I have received "substantial financial support and honoraria" from Abbott Laboratories (Abbott Park, IL). Perhaps a careful review of my income statements would have eliminated their adjective "substantial." Importantly, Hospira Inc. (Lake Forest, IL) owns and markets dexmedetomidine, and they claim no financial relationship to Abbott Laboratories and are listed as a separate company on the New York Stock Exchange. I have not received research funding from Hospira Inc. and do not speak on their behalf. Previously, Abbott Laboratories had marketed dexmedetomidine; my last support from them for a dexmedetomidine study was in 1999. The volunteer studies I refer to in our editorial were funded in the early 1990s. Based on the lack of support for studies with dexmedetomidine for 5 yr and the absence of speaking on this topic on behalf of Hospira Inc, I stand by the strict interpretation of my attestation at the time of the publication of our editorial.

Thomas J. Ebert, M.D., Ph.D., Medical College of Wisconsin and Zablocki VA Medical Center, Milwaukee, Wisconsin. tjebert@mcw.edu

Reference

1. Ebert T, Maze M: Dexmedetomidine: Another arrow for the clinician's quiver. ANESTHESIOLOGY 2004; 101:568–70

(Accepted for publication January 18, 2005.)
in the last sentence of the editorial did they offer the suggestion that dexmedetomidine may have a place in the management of the difficult airway. They recommended further comparative studies to establish the clinical role of dexmedetomidine in difficult airway algorithms. I certainly agree that three case reports are not even enough data to claim an ‘outcomes’ clinical trial; these reports were just observations. However, I am collecting more case reports to add to my initial database. I am also involved in a multicenter prospective clinical trial that is including the use of higher doses of dexmedetomidine than currently on the label and administering them for longer periods of time.

I wholeheartedly support the notion of evidence-based medicine following rigorous randomized controlled clinical trials, but the low incidence of the types of cases we reported will make this difficult to achieve in this patient population.

The “off-label” use of drugs is not unusual in the practice of anesthesiology, especially in some of our more sensitive patient groups such as the pediatric population. I agree with Mychaskiw and Badr that the use of “off-label” drugs needs to be done with extreme caution and is only justified when current therapies are less than optimal.

We thank Drs. Mychaskiw and Badr for raising a cautionary note about the use of these high doses of dexmedetomidine and we certainly emphasize that this should only be done by those practitioners with extensive experience with this drug in well-controlled circumstances and where current technologies are less than ideal. However, as our experience with dexmedetomidine increases, its role in the management of the difficult airway may well become “Another Arrow in the Clinician’s Quiver”!

Michael A. E. Ramsay, M.D., F.R.C.A., Baylor University Medical Center, Dallas, Texas. docram@baylorhealth.edu

Reference

1. Ramsay MAE, Luterman DL. Dexmedetomidine as a total intravenous agent. ANESTHESIOLOGY 2004; 101:787–90

To the Editor:—In the article by Johnson et al.1 and in the follow-up editorial by Shafer2 the sensitivity of pigs to propofol after severe hemorrhage is described. In the editorial, the “take-home message” is that propofol is a poor choice for induction. My supplementary “take-home” message is that a monitor of anesthetic depth, such as the Bispectral Index, should be used for all critically ill patients. If a dose of propofol drives the Bispectral Index to 0 (isoelectricity), the patient is probably too deeply anesthetized. Certainly, it is possible that the Bispectral Index is not accurate during shock, i.e., a decrease in Bispectral Index score might not necessarily represent a change in depth of anesthesia. In a case report of a patient who underwent elective abdominal aortic aneurysm repair with total intravenous anesthesia, the Bispectral Index score decreased shortly after the aortic clamp was released; 10 min later other monitored variables suggested clinical deterioration.3 Although no study has formally analyzed the relationship of Bispectral Index to shock, there are electroencephalographic changes during shock. In awake animal studies of controlled hemorrhagic shock, electroencephalography frequency slows and amplitude increases; the electroencephalograph is flat when blood pressure is inadequate to support respiration.4,5 It is not always clear how much anesthesia critically ill patients need. In such situations, I use a depth of anesthesia monitor, use much less anesthesia than I would otherwise have planned to use, and I believe that I also have an easier job of managing blood pressure.

J. Lance Lichtor, M.D., University of Iowa, Iowa City, Iowa. lance-lichtor@uiowa.edu

References


(Accepted for publication January 19, 2005.)

To the Editor:—It has been reported that hemorrhagic shock altered pharmacodynamics of propofol: the potency of propofol increased during hemorrhagic shock.1,2 A proposed explanation for this increase of propofol potency is that hemorrhagic shock leads to an increase in circulating beta endorphins.3 Recent work by Depaepe et al., however, has revealed that endorphin antagonism with naloxone does not influence end-organ sensitivity during hemorrhagic shock in the rat.2 Other potential sources of increased end-organ sensitivity to propofol is the increase of unbound propofol; this can be achieved through competitive displacement interactions with other drugs or endogenous substances or decreases in the level of proteins.

It is now widely accepted that the pharmacological effects of a drug are elicited by the unbound fraction in the blood. Only those drug molecules that are not bound to plasma protein are able to pass through blood vessels and reach their target sites within the tissue. Therefore, changes in the protein-binding characteristics of a drug may alter its pharmacological potency and pharmacokinetics. For drugs that are restrictively cleared, regardless of route of admin-

Anesthesiology 2005; 102:1068–9

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Depth of Anesthesia Monitors and Shock

Anesthesiology 2005; 102:1068

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Pharmacodynamics of Propofol during Hemorrhagic Shock

Anesthesiology 2005; 102:1068–9

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Downloaded from anesthesiology.pubs.asahq.org by guest on 02/07/2019
istration, an increase in the unbound fraction leads to accelerated total body clearance, thereby reducing the total concentration of drug. The unbound concentration at steady state is unchanged because an increase in the unbound concentration gradually returns to the control value after redistribution. Thus the ultimate effect of changes in protein binding is only transient.

In contrast, for drugs that are nonrestrictively cleared and administered intravenously, an increase in the unbound fraction could not affect total body clearance because such drugs are extracted by the eliminating organ so efficiently that protein binding dose not limit their removal. The total concentration of drug would initially fall because an increase in the unbound fraction leads to an increase in the volume of distribution. However, after redistribution the concentration returns to the control value. Thus, the total concentration at steady state is unchanged and an increase in the unbound fraction leads to an immediate and sustained increase in the unbound concentration. This is of clinical significance for highly protein-bound drugs with narrow therapeutic indices such as propofol.

Recently, we reported that a significant (twofold) increase in the concentration of unbound propofol occurred without alteration in the total propofol concentration in blood during cardiopulmonary bypass. This increase in the unbound fraction was caused mainly by a lower concentration of albumin. The increase of propofol potency during as a result of the loss of serum albumin accompanying hemorrhage—especially followed by crystalloid resuscitation.

Daisuke Takizawa, M.D.*, Eri Sato, M.D., Dai Kurosaki, Ph.D., Haruhiko Hiraoka, Ph.D., Ryuya Horiiuchi, Ph.D., Fumio Goto, Ph.D.* Gunma University, Graduate School of Medicine, Maebashi, Japan. dtakiz@bfo.so-net.ne.jp

References


(Received for publication January 19, 2005.)

In Reply—We thank Drs. Lichtor and Takizawa et al. for their interest in our study and thought-provoking observations. Dr. Lichtor points out that in settings of hypotensive extrems from blood loss i) perfusion to the brain can be compromised to the point of significantly altering electrical activity in the brain and ii) delivering an anesthetic that results in brain isoelectricity is clearly excessive. It is interesting to note that in our experimental protocol, we performed a series of pilot studies directed at characterizing the impact of our hemorrhage and resuscitation protocol on a processed measure of brain electrical activity, the Bispectral Index score, in the presence of isoflurane. Although hemorrhage was severe (+2 ml/kg) and resuscitation restored hemodynamic parameters to near-baseline levels, we observed no significant change in the Bispectral Index (i.e., no Bispectral Index decrease beyond that initially produced by isoflurane). We point out, however, that in our protocol, the mean arterial blood pressure never dropped below 40 mmHg and resuscitation was initiated just at the onset of cardiovascular decompensation. The clinical correlates here are twofold: 1) although hypotensive, compensatory mechanisms most likely maintained adequate cerebral perfusion to sustain brain electrical activity, and 2) resuscitation was initiated before going beyond a time that loosely coincides with the end of the “golden hour.” Once in a severely hypotensive (i.e., less than a mean arterial blood pressure of 40 mmHg) or in a decompensated cardiovascular state (e.g., beyond the “golden hour”), brain electrical activity may be dramatically altered, as suggested by the studies referenced in Dr. Lichtor’s letter.

Dr. Lichtor also points out that although the dose response of blood loss to changes in the Bispectral Index is not well defined, Bispectral Index can be useful in titrating an anesthetic. We concur with his recommendations that monitoring brain electrical activity during surgeries associated with excessive hemorrhage may offer a pragmatic approach to titrating the appropriate dose of anesthetic when the consequences of overdosing can be unpredictable.

In a previous study, we reported that blood loss alone led to a dramatic change in the pharmacokinetics and pharmacodynamics of propofol. In a follow-up study, we explored whether or not resuscitation would reverse these shock-induced changes in propofol kinetics and dynamic behavior. The most compelling finding was that despite resuscitation with crystalloid to near-baseline hemodynamics, the pharmacologic behavior of propofol was still altered when compared with controls. We concluded that hemorrhagic shock followed by resuscitation with lactated Ringer’s solution nearly restored the pharmacokinetic profile of propofol to a pre-hemorrhage state, but that resuscitation did not reverse the pharmacodynamic changes.

From a pharmacokinetic analysis standpoint, our work was primarily observational. We measured plasma propofol levels and estimated volumes and clearances using compartmental models and used these estimates to make comparisons between study groups. We did not make measurements that would allow us to discover how drug distribution and clearance were altered by hemorrhagic shock and resuscitation. For example, we did not measure or estimate i) plasma protein content, ii) propofol-plasma protein binding, or iii) unbound propofol levels throughout our experimental protocol. Furthermore, we did not measure how the initial distribution and subsequent redistribution of propofol was altered following blood loss and resuscitation or how altered plasma pH levels may have impacted unbound propofol availability. Finally, we did not explore to what extent the clearance of unbound propofol by metabolic organs would be compromised by our experimental protocol (e.g., a comparison of hepatic extraction ratios for propofol between control and bled-resuscitated animals).

As suggested by Dr. Takizawa et al., what we reported as an increase in end-organ sensitivity to propofol may be, at least in part, attributable to an unrecognized increase in unbound propofol. Thus our reported leftward shift in the C50 of propofol may represent an undetected pharmacokinetic difference between groups. Although the measured plasma propofol levels were comparable between the control and hemorrhage-resuscitation groups, the amount of unbound propofol available to exert a pharmacologic effect may have been increased. After removing more than 50% of the estimated blood volume and...
To the Editor:—We report the case of a 68-yr-old obese male patient that was admitted to our university hospital for scheduled elective left carotid endarterectomy under regional anesthesia. Past medical history was significant, with controlled ischemic (four coronary artery bypass grafts at the age of 56 yr) and hypertensive cardiopathy and sleep apnea syndrome balanced with nocturnal ventilation support. Preoperative physical examination detected no abnormality. The patient received a deep cervical plexus block using a single-injection (15 ml 0.5% bupivacaine and 15 ml 2% lidocaine) nerve stimulator-assisted technique. The patient developed respiratory distress associated with bilateral diaphragm paralysis symptoms 15 min after the block was placed. Facemask noninvasive titrated inspiratory pressure-support ventilation resulted in normal breathing pattern and oxygen parameters. After an uneventful surgical procedure the patient was transferred to the ward 2 h after postanesthesia care unit admission. Postoperative ambulatory arterial blood gas analysis and pulmonary functional tests were considered subnormal but phrenic conduction measurements confirmed severe right phrenic nerve conduction alteration.

In this report the patient experienced acute ventilatory failure probably attributable to bilateral diaphragm weakness. Epidural or subarachnoid injection might have promoted similar clinical features. However, the deep cervical plexus block we performed remained strictly ipsilateral to the puncture side. The block concerned left C2-C4 sensory dermatomes but preserved distal motor function of the arm. Then, we believe that the spread of deep cervical plexus block promoted a left phrenic block, resulting in ventilatory failure because of preexisting contralateral phrenic damage. Usually, extension of the block to the phrenic nerve is common during cervical blocks but without significant clinical problems, even in patients with preexisting lung disease. In the present case, unrecognized coronary artery bypass graft-induced right phrenic nerve damage was revealed by the extension of left deep cervical plexus block.

Because up to 10% of cardiac surgery patients may suffer from postoperative electrophysiological abnormal phrenic nerve conduction, we recommend anesthesiologists performing cervical blocks in postcardiac surgery patients remain vigilant attending the patient, with the capacity to supply ventilatory support.

Gilles D’Honneur, M.D.,* Cyrus Motamed, M.D., Loïc Tual, M.D., Xavier Combes, M.D.,* University Hospital Henri Mondor, Creteil Cedex, France. gilles.dhonneur@jvr.ap-hop-paris.fr

References

Support was provided solely from institutional and/or departmental sources.

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Anesthesiology 2005; 102:1070–1

To the Editor:—Recall during general anesthesia has been reported to occur in approximately 1 to 2 per 1000 anesthetic procedures. Most providers are familiar with press reports and litigations by patients to recover damages as a result of recall and suffering while under general anesthesia. I would like to report a phenomenon which I have observed to be occurring more frequently in my practice.

During my preoperative visit, I commonly ask the patient about previous anesthetic exposures. Lately, several patients have stated that they remember most if not all of their last anesthetic. When asked what type of procedure they had that they recall so well, they have invariably replied, colonoscopy, cataract, cardiac catheterization, or similar procedures. When I question this recall event further, it is clear that the procedure they recall was done under sedation and not general anesthesia. Indeed, all of the patients I have interviewed so far who have had other procedures that required general anesthesia, e.g., cholecystectomy, were able to discern the difference in the depth of anesthesia and had no recall of the block to the phrenic nerve is common during cervical blocks but without significant clinical problems, even in patients with preexisting lung disease. In the present case, unrecognized coronary artery bypass graft-induced right phrenic nerve damage was revealed by the extension of left deep cervical plexus block.

Because up to 10% of cardiac surgery patients may suffer from postoperative electrophysiological abnormal phrenic nerve conduction, we recommend anesthesiologists performing cervical blocks in postcardiac surgery patients remain vigilant attending the patient, with the capacity to supply ventilatory support.

Gilles D’Honneur, M.D.,* Cyrus Motamed, M.D., Loïc Tual, M.D., Xavier Combes, M.D.,* University Hospital Henri Mondor, Creteil Cedex, France. gilles.dhonneur@jvr.ap-hop-paris.fr

References

Support was provided solely from institutional and/or departmental sources.

© 2005 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Anesthesiology 2005; 102:1070–1
First, find out if they truly had a general anesthetic. Second, do not make assurances of memory ablation if you do not plan a general anesthetic and even then be careful what you promise. Third, talk with your colleagues in the endoscopy and catheterization laboratories. I think they are making well-intentioned assurances of memory ablation and are unaware of how often they fail to provide the amnesia they wish to give.

Harold W. Collier, M.D., University of Kansas School of Medicine, Wichita, Kansas. hwcollier@hotmail.com

References


(Accepted for publication January 7, 2005.)